Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 22 of 46

Controlled Studies in This CER: Adding Biologic DMARDs to JIA Treatment (1 of 2)

There are few studies of biologic DMARDs in children with JIA, and the numbers of treated and control group patients are limited. Methotrexate or other nonbiologic DMARDs—along with NSAIDs, oral corticosteroids, and analgesics—were permitted in the comparison group in most studies.

One study of abatacept included 5 patients with persistent oligoarticular disease, 43 with extended oligoarticular disease, 205 with polyarticular disease, and 60 with systemic disease. One study of adalimumab included 171 patients with polyarticular disease. One study of anakinra included 33 patients with polyarticular disease, 6 with pauciarticular disease, and 11 with systemic disease. One study of tocilizumab included 43 patients with undefined JIA.